Agenda

WELCOMING REMARKS

• Philip Landrigan, MD, Dean of the Global Health Program at Mount Sinai School of Medicine
• Deane Marchbein, MD, President of MSF-USA

• Rachel Cohen, Regional Executive Director DNDi North America 

  Follow @DNDi_HQ

KEYNOTE ADDRESS

Anthony S. Fauci, MD, Director, National Institute of Allergy and Infectious Diseases, US National Institutes of Health 

Follow @NIAIDNews

PANEL 1.1: Global Progress and Shortcomings of the Past Decade

Panel Chair: Dyann Wirth, PhD, Richard Pearson Strong Professor of Infectious Diseases, Harvard School of Public Health 

Follow @HarvardHSPH

• Manica Balasegaram, MD, Executive Director, MSF Access Campaign - The urgent need for new tools for DR-TB 

  Follow @msf_access

• Julio A. Urbina, PhD, Venezuelan Institute for Scientific Research - Reaching neglected patients with Chagas treatment 
• F. Marc LaForce, MD, Director, Technical Services, Serum Institute of India, Ltd - Overview of vaccine initiatives of the past decade

Discussants:

• Atadjan Karimovich Khamraev, MD, Vice-Chairman of the Supreme Assembly of the Autonomous Republic of Karakalpakstan

• Peter J. Hotez, MD, PhD, Dean, National School of Tropical Medicine, Baylor College of Medicine

  Follow @PeterHotez

• H.E. Dr. Josephine Ojiambo, MB ChB, MPH, Ambassador, Deputy Permanent Representative of the Republic of Kenya to the United Nations

Panel Chair: Els Torreele, PhD, Director, Open Society Public Health Program's Access to Essential Medicines Initiative 

Follow @ElsTorreele

Presenters:

• Carlos Morel, MD DSc, Scientific Coordinator, Center for Technological Development in Health (CDTS) at the Oswaldo Cruz Foundation (Fiocruz) – What steps have been taken to address gaps in R&D for neglected patients over the last twenty years: A View from the South  

  Follow @cmmorel

• Jean-Herve Bradol, MD, Research Director, MSF’s Centre de réflexion sur l'action et les savoirs humanitaires (CRASH) – Fatal Imbalance: Update and expanded review of new treatments and current pipeline of clinical trials for neglected diseases, 2000-2011 

• John-Arne Røttingen, MD, PhD, Chair, Consultative expert working group on research and development (CEWG) – A possible framework for stimulating medical innovations for neglected patients 

  Follow @jarottingen

Discussants:

• Lucy Chesire, Director, TB ACTION Group, Kenya

• James Love, Director, Knowledge Ecology International 

  Follow @jamie_love

• Christian Loucq, MD, Director General International Vaccine Institute (IVI)

Opening Talk: Jim Y. Kim, MD, President, World Bank Group (Video Address)

Roundtable 1.3: Setting Priorities for Global Health to Ensure Innovation and Access

Moderator: Gavin Yamey, MD, MA, MRCP, Lead of E2Pi, the Evidence-to-Policy Initiative at the UCSF Global Health Group 

Panelists:

• Carlos Gadelha, PhD, Secretary of Science, Technology and Strategic Products (SCTIE), Ministry of Health, Brazil 
• Marie-Paule Kieny, PhD, Assistant Director-General - Innovation, Information, Evidence and Research, World Health Organization
• Dan Hartman, MD, Director, Integrated Development, Global Health Program, Bill & Melinda Gates Foundation
• ‘Rolake Odetoyinbo, Director, Positive Action for Treatment Access (PATA), Nigeria

• Manica Balasegaram, MD, Executive Director, MSF Access Campaign

  Follow @msfaccess

Moderator: Ellen ‘t Hoen, LL.M., Research Fellow at the University of Amsterdam and Senior Advisor of the Medicines Patent Pool

Follow @ellenthoen

Panelists:

• Roger I. Glass, MD, PhD, Director of the Fogarty International Center and Associate Director for International Research by NIH, US National Institutes of Health
• Christopher A. Viehbacher, Chief Executive Officer, Sanofi
• Gichinga Ndirangu, Africa Coordinator, Health Action International (HAI) 
• Samir K. Brahmachari, PhD, Director General, Council of Scientific and Industrial Research, India

• Bernard Pecoul, MD, Executive Director of Drugs for Neglected Diseases initiative (DNDi)

  Follow @DNDi_HQ

Marie-Pierre Allie, MD, President of MSF in France

The need to accelerate the delivery of medical innovations to neglected patients

Bennett Shapiro, PureTech Ventures and DNDi Board Member

Moderator: Arjan Hehenkamp, General Director, MSF Operational Center Amsterdam

Follow @Arjan_Hehenkamp

Short presentations to set the stage:

• Francis Varaine, MD, Head of MSF’s TB Working Group – Outcomes with current DR-TB treatment and urgent need for change
• Mel Spigelman, MD, President and CEO, TB Alliance – The current pipeline and scheduled plans for when molecules will be available 
• Dalene von Delft, MD– A patient’s perspective of current DR-TB treatment 

Panel Discussion:

• Atadjan Karimovich Khamraev, Vice-Chairman of the Supreme Assembly of the Autonomous Republic of Karakalpakstan
• Carole Mitnick, ScD, Assistant Professor of Global Health and Social Medicine, Harvard Medical School 

• Mark Harrington, Executive Director, Treatment Action Group (TAG)

  Follow @TAGTeam_Tweets

• Wim Parys, MD, Global Head, Infectious Diseases, Janssen Infectious Diseases BVBA

Moderator: Isabela Ribeiro, MD, Head of Chagas Clinical Program, DNDi

Short Presentations Setting the Stage:

• Jose Rivero, International Federation of People Suffering from Chagas Disease, Spain – A patient’s perspective of Chagas disease treatment

  Follow @josesitori

• Carolina Batista, MSF Brazil and Henry Rodriguez, MD, MSF Head of Mission in Bolivia and Paraguay– Obstacles and challenges of treating Chagas disease 
• Faustino Torrico, M.D., Ph.D., Professor, Faculty of Medicine, Universidad Mayor de San Simon, Cochabamba, Bolivia – The current pipeline for Chagas disease

Panel Discussion:

• Jaime Lazovski, Secretary of Health Relations and Research, Ministry of Health, Argentina
• Sheba Meymandi, MD, Director, Centre of Excellence for Chagas Disease, Olive View/UCLA Medical Center
• Sonia Tarragona, General Director, Foundation Mundo Sano, Argentina
• Pedro Alonso, MD, Director, Barcelona Center for International Health Research (CRESIB), University of Barcelona

Moderator: Robert Steinglass, Immunization Senior Advisor, John Snow, Inc. (JSI) and Immunization Team Leader, MCHIP 

Short Presentations Setting the Stage:

• Samba Ousmane Sow, MD, Center for Vaccine Development-Mali (CVD-Mali) – A case study on using TT-Uniject in Mali 
• Rebecca Grais, PhD , Epicentre – Optimizing vaccinations in emergencies – what products are needed

Panel Discussion:

• Fred Were, MD, Chairman of the Kenya Pediatric Association
• F. Marc La Force, MD, Serum Institute of India
• Nina Schwalbe, Managing Director, Policy & Performance, GAVI Alliance

• Paul Herrling, PhD, 

  Professor, 

  Chair Novartis Institute for Tropical Diseases, 

  Novartis Pharma AG

Marcel Tanner, PhD, Director of the Swiss Tropical and Public Health Institute and Chair of the Board of Directors, DNDi